Clone REAL172 is an antibody fragment derived from the full CD101 antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAlease Complex to bind markers with high avidity.
Clone REAL172 recognizes the mouse CD101 antigen, a type I transmembrane glycoprotein also known as Immunoglobulin superfamily member 2 (IgSF2) or V7. CD101 is expressed on monocytes, granulocytes, dendritic cells (DCs), and activated T cells. In humans CD101 inhibits the proliferative response of T cells to allogeneic cells or immobilized anti-CD3 antibody, suggesting that engagement of CD101 can antagonize TCR/CD3-mediated lymphocyte activation. Moreover, human peripheral CD8
+ T cells that express CD101 and CD103 display suppressive function after activation with intraepithelial cells or placental trophoblasts. In addition to its role on T cells, triggering CD101 on human cutaneous DC inhibits T cell proliferation via interleukin 10 (IL-10) production, suggesting that the CD101 molecule may be involved in tolerance induction. Studies in mice showed that cell surface expression of CD101 is highly correlated with functional suppressor activity within CD4
+CD25
+ regulatory T cells both
in vitro and
in vivo.
The REAlease Kits consist of the respective fluorochrome-conjugated REAlease Complexes and the REAlease Support Kit for removal of the REAlease Complexes and optional relabeling with different fluorochrome-conjugated REAlease Complexes.
